United States - English - NLM (National Library of Medicine)

greenstone llc - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: essential hypertension: control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc)

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: usage in pregnancy. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions  for patients with: congestive heart failure: cirrhosis of the liver accompanied by edema and/or ascites: the nephrotic syndrome: essential hypertension: control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progra

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: congestive heart failure: - for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; - the treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; - the treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. cirrhosis of the liver accompanied by edema and/or ascites: - aldosterone levels may be exceptionally high in this cond

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone 25 mg - spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. the treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. the treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. aldosterone levels may be exceptionally high in this condition. spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. for nephrotic patients when treatment of the und

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets, usp should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: congestive heart failure: cirrhosis of the liver accompanied by edema and/or ascites: the nephrotic syndrome: essential hypertension: the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologi

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: - for the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; - the treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; - the treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. - aldosterone levels may be exceptionally high in this condition. spironolactone and hydrochlorothiazide tablets are indicated for maintenance t

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: usage in pregnancy. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: usage in pregnancy. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see precautions: pregnancy ). dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. there is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. if this edema produces discomfort, increased recumbency will often provide relief. in rare instances, this edema may cause extreme discomfort that is not relieved by rest. in these cases, a short course of diuretics may provide relief and may be appropriate. spironolactone and hydrochlorothiazide tablets are contraindicated in patients with anuria, acute renal insufficiency, significant impairment of renal excretory function, hypercalcemia, hyperkalemia, addison's disease, and in patients who are allergic to thiazide diuretics or to other sulfonamide-derived drugs. spironolactone and hydrochlorothiazide tablets may also be contraindicated in acute or severe hepatic failure.

United States - English - NLM (National Library of Medicine)

prasco laboratories - spironolactone (unii: 27o7w4t232) (spironolactone - unii:27o7w4t232), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see precautions section). spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. unnecessary use of this drug should be avoided. spironolactone and hydrochlorothiazide tablets are indicated for: edematous conditions for patients with: congestive heart failure: cirrhosis of the liver accompanied by edema and/or ascites: the nephrotic syndrome: essential hypertension: control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr